The Catalan blood products company has received a $21 million grant from the Michael J. Fox Foundation (MJFF) for Parkinson's ...

Grifols, a global healthcare company and leading producer of plasma-derived medicines, today announced it has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to ...

The Michael J. Fox Foundation for Parkinson’s Research has partnered with Grifols, a global healthcare company, to identify ...

Will fund a pilot study to analyze longitudinal plasma samples covering a period of up to 10 years.

Grifols has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to identify plasma-based ...

The unique plasma assets serve as the foundation of the Chronos-PD program, driving advanced research at Grifols subsidiary Alkahest, which is leading the initiative given its specialization in the ...

Grifols, S.A. operates as a plasma therapeutic company in ... and plasma exchange with albumin used to treat Alzheimer’s disease. It markets diagnostic testing equipment, reagents, and other equipment ...

Immune globulin (human) is under clinical development by Grifols and currently in Phase II for Coronavirus Disease 2019 (COVID-19).

Spanish plasma-based medicines maker Grifols (MCE: GRF) has announced disappointing top-line data from its Phase III PRECIOSA clinical trial evaluating the potential of long-term albumin treatment ...